NumerixS Investment Technologies Inc boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3,500.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,600 shares of the pharmaceutical company’s stock after purchasing an additional 3,500 shares during the period. NumerixS Investment Technologies Inc’s holdings in Vertex Pharmaceuticals were worth $656,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its position in shares of Vertex Pharmaceuticals by 16,530.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares during the period. FMR LLC increased its stake in shares of Vertex Pharmaceuticals by 13.3% in the fourth quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock worth $3,394,256,000 after acquiring an additional 2,411,631 shares during the period. Norges Bank acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $380,584,000. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 11.9% in the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after acquiring an additional 739,128 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Vertex Pharmaceuticals by 2.9% in the first quarter. BlackRock Inc. now owns 20,176,298 shares of the pharmaceutical company’s stock worth $3,711,428,000 after acquiring an additional 568,488 shares during the period. Institutional investors own 94.94% of the company’s stock.
In related news, SVP Paul M. Silva sold 161 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total value of $26,631.01. Following the completion of the sale, the senior vice president now owns 17,759 shares in the company, valued at approximately $2,937,516.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Stuart A. Arbuckle sold 5,624 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $181.75, for a total transaction of $1,022,162.00. Following the completion of the sale, the executive vice president now owns 36,272 shares of the company’s stock, valued at approximately $6,592,436. The disclosure for this sale can be found here. In the last quarter, insiders sold 223,554 shares of company stock valued at $39,194,006. 0.70% of the stock is owned by insiders.
Several brokerages have recently issued reports on VRTX. BidaskClub upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, March 8th. JPMorgan Chase & Co. restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Sunday, June 2nd. Evercore ISI initiated coverage on shares of Vertex Pharmaceuticals in a report on Thursday, April 11th. They set an “in-line” rating and a $183.00 price target for the company. Finally, ValuEngine cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eighteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $204.36.
Shares of NASDAQ:VRTX traded down $2.49 during trading on Wednesday, hitting $177.66. 632,981 shares of the company were exchanged, compared to its average volume of 1,348,914. The stock has a market capitalization of $45.50 billion, a PE ratio of 62.78, a P/E/G ratio of 2.63 and a beta of 1.48. The company has a quick ratio of 3.66, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. Vertex Pharmaceuticals Incorporated has a 12-month low of $145.37 and a 12-month high of $195.81. The company has a 50 day moving average of $172.05.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The firm had revenue of $857.00 million during the quarter, compared to the consensus estimate of $853.00 million. During the same quarter in the prior year, the firm earned $0.76 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 34.3% on a year-over-year basis. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current fiscal year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: Find a Trading Strategy That Works
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.